Key facts
- GLP-1 obesity drugs are showing promise in treating polyendocrine metabolic ovarian syndrome (PMOS).
- Research indicates these drugs improve weight loss, insulin resistance, hormone balance, and ovulation in PMOS patients.
- Charlotte Touzalin experienced significant symptom improvement, including weight loss and normalized periods, after taking semaglutide.
- A study showed participants lost an average of 42 pounds and experienced a 52% drop in testosterone.
- Insurance coverage for GLP-1 drugs for PMOS is often a barrier due to off-label use.
Charlotte Touzalin, an 18-year-old college student, has found new hope in a study testing GLP-1 obesity drugs for polyendocrine metabolic ovarian syndrome (PMOS), a hormonal disorder that also affected her mother, Anne Schultz, for decades. Touzalin experienced symptoms including weight gain, abnormal periods, and unwanted facial hair, common hallmarks of PMOS, a condition that often takes years to diagnose due to its varied and overlapping symptoms.
Unlike her mother, Touzalin is benefiting from emerging research suggesting that blockbuster GLP-1 medications, such as semaglutide, can effectively treat PMOS. Beyond promoting weight loss, these drugs appear to improve key aspects of the condition, including insulin resistance, hormone balance, and ovulation. Dr. Melanie Cree, who led the study Touzalin participated in, described the findings as "incredibly effective and really exciting."
Touzalin's 10-month treatment with semaglutide resulted in significant weight loss, normalized periods, and a reduction in abnormal hair growth. She reported feeling fuller after eating and experiencing a halt in constant weight gain, leading to a happier state of being. Early data from the study, published in Fertility and Sterility, showed that eight out of eleven participants lost at least 10% of their body weight, with a median loss of 42 pounds and a 52% drop in testosterone levels. Six women experienced more regular periods.
While research continues and doctors increasingly prescribe GLP-1s off-label for PMOS, insurance coverage remains a significant hurdle. The drugs are not approved for treating PMOS, and some insurers do not cover them even for weight loss, a frustration for both patients and physicians like Dr. Rana Malek, who frequently uses these medications for patients with insulin resistance.